Spectrum of Autoimmune Liver Disease and Real-World Treatment Experience from a Tertiary Care Hospital

被引:12
作者
Taneja, Sunil [1 ]
Mehtani, Rohit [1 ]
De, Arka [1 ]
Mitra, Suvradeep [2 ]
Rathi, Sahaj [1 ]
Verma, Nipun [1 ]
Premkumar, Madhumita [1 ]
Minz, Ranjana [2 ]
Duseja, Ajay [1 ]
Das, Ashim [3 ]
Singh, Virendra [1 ]
Dhiman, Radha K. [1 ]
Chawla, Yogesh K. [1 ]
机构
[1] Post Grad Inst Med Educ & Res, Dept Hepatol, Chandigarh, India
[2] Post Grad Inst Med Educ & Res, Dept Immunopathol, Chandigarh, India
[3] Post Grad Inst Med Educ & Res, Dept Histopathol, Chandigarh, India
关键词
autoimmune hepatitis; primary biliary cholangitis; primary sclerosing cholangitis; overlap syndromes; cirrhosis; PRIMARY SCLEROSING CHOLANGITIS; DOSE URSODEOXYCHOLIC ACID; BIOCHEMICAL RESPONSE; NATURAL-HISTORY; HEPATITIS; MULTICENTER; CIRRHOSIS;
D O I
10.1016/j.jceh.2022.11.002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims: Autoimmune liver disease (AILD) comprises of autoimmune hepatitis (AIH), primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) with a spectrum of overlap amongst the three. We analyzed the spectrum and treatment outcomes of patients with AILD presenting to a tertiary care center in India. Methods: A retrospective analysis of AILD patients from June 2008 to April 2021 was performed. The diag-nosis was based on clinical, biochemical, imaging, serological, and histological characteristics. Eligible patients received treatment depending on the disease stage. Biochemical response to treatment was defined as normali-zation of AST, ALT, bilirubin, and immunoglobulin G levels at 6 months in AIH, normalization of total bilirubin and/or albumin at 1 year in PBC and decrease in alkaline phosphatase (ALP) levels by 40% in PSC. Results: Two hundred seventy-five patients were analyzed. AIH (58.54%) was most common, followed by an overlap of AIH-PBC (24%) and AIH-PSC (6.54%), PSC (6.18%), and PBC (4.72%). Most patients presented in 3rd or 4th decade, except PBC which occurred predominantly in 5th decade. The majority of patients were females (72.72%). Jaun-dice was the most common presentation seen in 60% of patients. Cirrhosis was present in 57.47% of patients. Pa-tients with overlap had more pruritus (54.76 vs 6.83%), fatigue (63.1% vs 49.7%), hepatomegaly (52.4% vs 25.5%), and higher ALP (80.9% vs 37.7%) than patients with AIH alone. Acute presentation was seen in 33 patients (13.5%) with most having AIH flare. Five patients had acute liver failure (ALF) and 9 had acute-on-chronic liver failure (ACLF). ALF was associated with 80% mortality while 55.56% of patients with ACLF had a complete biochemical response to immunosuppression. Among patients with AIH and/or overlap who received immunosuppression, a complete biochemical response to immunosuppression was seen in 60.69% of patients. High ALT (OR 1.001 [1.000-1.003], P = 0.034), high albumin (OR 1.91 [1.05-3.48], P = 0.034) and low fibrosis on biopsy (OR 0.54 [0.33-0.91], P = 0.020) predicted complete response. Conclusion: AIH is the most common AILD followed by over-lap syndromes, PSC and PBC in our cohort. Biochemical response to immunosuppression is seen in 60% of pa-tients with AIH & low fibrosis score on histopathology predicts a complete response. ( J CLIN EoHEPATOL 2023;13:241-251)
引用
收藏
页码:241 / 251
页数:11
相关论文
共 30 条
[1]   The Spectrum of Autoimmune Liver Disorders, Clinical Presentation, and Autoantibodies in Patients From a Tertiary Care Center in Pakistan [J].
Abbas, Zaigham ;
Asim, Muhammad ;
Saeed, Alina ;
Siddiqui, Basit ;
Abbas, Minaam .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (11)
[2]   Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival [J].
Al-Chalabi, T. ;
Portmann, B. C. ;
Bernal, W. ;
Mcfarlane, I. G. ;
Heneghan, M. A. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (02) :209-220
[3]   Acute onset autoimmune hepatitis: Clinical presentation and treatment outcomes [J].
Aljumah, Abdulrahman A. ;
Al-Ashgar, Hamad ;
Fallatah, Hind ;
Albenmousa, Ali .
ANNALS OF HEPATOLOGY, 2019, 18 (03) :439-444
[4]   Spectrum of autoimmune liver diseases in western India [J].
Amarapurkar, Deepak N. ;
Patel, Nikhil D. .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (12) :2112-2117
[5]   Flare of Autoimmune Hepatitis Causing Acute on Chronic Liver Failure: Diagnosis and Response to Corticosteroid Therapy [J].
Anand, Lovkesh ;
Choudhury, Ashok ;
Bihari, Chhagan ;
Sharma, Barjesh C. ;
Kumar, Manoj ;
Maiwall, Rakhi ;
Tan, Soek Siam ;
Shah, Samir R. ;
Hamid, Saeed ;
Butt, Amna S. ;
Jafri, Wasim ;
Chawla, Yogesh K. ;
Taneja, Sunil ;
Duseja, Ajay ;
Dhiman, Radha K. ;
Al Mahtab, Mamun ;
Ghazinyan, Hasmik ;
Duan, Zhongping ;
Chen, Yu ;
Shukla, Akash ;
Hu, Jinhua ;
Abbas, Zaigham ;
Treeprasertsuk, Sombat ;
Lesmana, Laurentius A. ;
Lesmana, Cosmas R. ;
Sollano, Jose D. ;
Carpio, Gian ;
Sahu, Manoj K. ;
Kumar, Guresh ;
Sarin, Shiv K. .
HEPATOLOGY, 2019, 70 (02) :587-596
[6]   Clinical profile of primary sclerosing cholangitis in Singapore [J].
Ang, TL ;
Fock, KM ;
Ng, TM ;
Teo, EK ;
Chua, TS ;
Tan, JYL .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (08) :908-913
[7]   Inflammatory Bowel Disease in Immigrants to Canada And Their Children: A Population-Based Cohort Study [J].
Benchimol, Eric I. ;
Mack, David R. ;
Guttmann, Astrid ;
Nguyen, Geoffrey C. ;
To, Teresa ;
Mojaverian, Nassim ;
Quach, Pauline ;
Manuel, Douglas G. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (04) :553-563
[8]   EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update [J].
Berzigotti, Annalisa ;
Tsochatzis, Emmanouil ;
Boursier, Jerome ;
Castera, Laurent ;
Cazzagon, Nora ;
Friedrich-Rust, Mireen ;
Petta, Salvatore ;
Thiele, Maja .
JOURNAL OF HEPATOLOGY, 2021, 75 (03) :659-689
[9]   EASL Clinical Practice Guidelines: Management of cholestatic liver diseases [J].
Beuers, Ulrich ;
Boberg, Kirsten M. ;
Chapman, Roger W. ;
Chazouilleres, Olivier ;
Invernizzi, Pietro ;
Jones, David E. J. ;
Lammert, Frank ;
Pares, Albert ;
Trauner, Michael .
JOURNAL OF HEPATOLOGY, 2009, 51 (02) :237-267
[10]  
Cancado ELR, 2000, AUTOIMMUNE HEPATITIS, P2